Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).
Enrico D, Gomez JE, Aguirre D, Tissera NS, Tsou F, Pupareli C, Tanco DP, Waisberg F, Rodríguez A, Rizzo M, Minatta N, Rafael P, Basbus L, Lupinacci L, Kaen D, Ramos M, Bluthgen V, Castagneris N, Coppola MP, Scocimarro A, Guerra MF, Perfetti A, Levit P, Galvez-Nino M, Mas L, Rojas L, Zuluaga J, Chacón M, Corrales L, Samtani S, Arrieta O, Cardona A, Remon J, Martín C.
Enrico D, et al. Among authors: aguirre d.
Clin Lung Cancer. 2024 Sep 21:S1525-7304(24)00200-6. doi: 10.1016/j.cllc.2024.09.005. Online ahead of print.
Clin Lung Cancer. 2024.
PMID: 39424512